Loading...
•
Sep 30, 2022
Kiniksa Q3 2022 Earnings Report
Reported third quarter 2022 financial results and provided a corporate update.
Key Takeaways
Kiniksa Pharmaceuticals reported strong ARCALYST performance in Q3 2022, driven by physician adoption, patient satisfaction, and payer access. The company is focused on positioning ARCALYST as the standard of care for recurrent pericarditis and is well-positioned to execute on synergistic growth opportunities across its portfolio.
ARCALYST Q3 2022 net revenue was $33.4 million.
RHAPSODY long-term extension data demonstrated continued rilonacept treatment response beyond 18 months (Hazard Ratio = 0.018, p<0.0001).
KPL-404 Phase 2 data in rheumatoid arthritis is expected in 1H 2024.
Cash reserves of $200.7 million are expected to fund operations into at least 2025.
Revenue by Segment
Forward Guidance
Kiniksa expects ARCALYST net revenue for full-year 2022 to be between $115 million and $130 million and cash reserves are expected to fund the current operating plan into at least 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...